Abstract
The mutational spectrum and prognostic factors of NRAS-mutated (NRASmut) acute myeloid leukemia (AML) are largely unknown. We performed next-generation sequencing (NGS) in 1,149 cases of de novo AML and discovered 152 NRASmut AML (13%). Of the 152 NRASmut AML, 89% had at least one companion mutated gene. DNA methylation-related genes confer up to 62% incidence. TET2 had the highest mutation frequency (51%), followed by ASXL1 (17%), NPM1 (14%), CEBPA (13%), DNMT3A (13%), FLT3-ITD (11%), KIT (11%), IDH2 (9%), RUNX1 (8%), U2AF1 (7%) and SF3B1(5%). Multivariate analysis suggested that age ≥ 60 years and mutations in U2AF1 were independent factors related to failure to achieve complete remission after induction therapy. Age ≥ 60 years, non-M3 types and U2AF1 mutations were independent prognostic factors for poor overall survival. Age ≥ 60 years, non-M3 types and higher risk group were independent prognostic factors for poor event-free survival (EFS) while allogenic hematopoietic stem cell transplantation was an independent prognostic factor for good EFS. Our study provided new insights into the mutational spectrum and prognostic factors of NRASmut AML.
References
Jan 1, 1997·Leukemia & Lymphoma·M B De MeloF F Costa
Jun 14, 2005·Blood·David T BowenDavid C Linch
Jan 26, 2006·Blood·Ulrike BacherSusanne Schnittger
Feb 22, 2008·Leukemia·A RennevilleC Preudhomme
Mar 6, 2012·Blood·Felicitas TholMichael Heuser
Jan 15, 2013·Clinical Biochemistry·Xiaofei YangDepei Wu
Apr 17, 2014·Annals of Hematology·Christoph W M ReuterMichael A Morgan
Oct 2, 2014·Blood·Richard F SchlenkUNKNOWN German-Austrian AML Study Group
Nov 22, 2014·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Robert S OhgamiDaniel A Arber
Apr 3, 2015·Blood·Atsushi NonamiJames D Griffin
Sep 17, 2015·The New England Journal of Medicine·Hartmut DöhnerClara D Bloomfield
Jan 23, 2016·American Journal of Hematology·Betty Ky HamiltonRamon V Tiu
Jan 27, 2016·Oncotarget·Hsin-An HouHwei-Fang Tien
Apr 14, 2016·Blood·Daniel A ArberJames W Vardiman
Jun 9, 2016·The New England Journal of Medicine·Elli PapaemmanuilPeter J Campbell
Jun 12, 2016·Blood·Klaus H MetzelerUNKNOWN AMLCG Study Group
Aug 11, 2016·Drug Discovery Today·Candice Y Wilson, Peter Tolias
Mar 16, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lars BullingerHartmut Döhner
Apr 12, 2017·Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·UNKNOWN Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association
Jan 13, 2018·Blood Cancer Journal·Caner SayginAnjali S Advani
May 5, 2018·Blood·Sanjay S PatelOlga K Weinberg
Aug 29, 2018·Journal of Medicinal Chemistry·Hanna ChoTaebo Sim
Sep 9, 2018·Clinica Chimica Acta; International Journal of Clinical Chemistry·Xin LiuXi-Long Zhao
Jan 11, 2020·Experimental Hematology & Oncology·Jifeng YuZhongxing Jiang